Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.54 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989885 | 0.90 | MAPK1 (0.43) | MAPK1HTR2AP2RX7 | |
| SCHEMBL30989892 | 0.88 | NTRK1 (0.46) | MAPK1TRPV1P2RX7 | |
| SCHEMBL30989929 | 0.85 | P2RX7 (0.42) | MAPK1TRPV1MEN1KMT2AP2RX7 | |
| SCHEMBL30989933 | 0.85 | P2RX7 (0.42) | MAPK1TRPV1MEN1KMT2AP2RX7 | |
| SCHEMBL30990021 | 0.83 | TAS1R3 (0.57) | MEN1KMT2AHPGDS | |
| SCHEMBL30989941 | 0.80 | MAPK1 (0.43) | MAPK1 | |
| SCHEMBL30990023 | 0.80 | MAPK1 (0.43) | MAPK1 | |
| SCHEMBL21875803 | 0.79 | MAPK1 (0.42) | MAPK1BRD4CREBBPTRPV1KMT2A | |
| SCHEMBL29438346 | 0.79 | MAPK1 (0.42) | MAPK1BRD4CREBBPTRPV1KMT2A | |
| SCHEMBL29965218 | 0.79 | MAPK1 (0.42) | MAPK1BRD4CREBBPTRPV1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |